Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • receipt Report ID : 150640
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 124
  • list Pharmaceuticals and Healthcare

Recurrent glioblastoma multiforme is the most aggressive cancer that begins within the brain.

Scope of the Report:

This report studies the Recurrent Glioblastoma Multiforme (GBM) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Recurrent Glioblastoma Multiforme (GBM) Treatment market by product type and applications/end industries.

The increasing incidence of seizure is expected to drive the recurrent glioblastoma multiforme treatment market.

The global Recurrent Glioblastoma Multiforme (GBM) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Recurrent Glioblastoma Multiforme (GBM) Treatment.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

Astrazeneca

Roche

GlaxoSmithKline

Merck

Pfizer

AngioChem

Vascular Biogeneics

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Oral Medications

Temozolomide

Radiosensitizers

Nitrosoureas Drugs

Radiation Therapy

Chemotherapy

Market Segment by Applications, can be divided into

Hospitals

Clinics

Ambulatory Surgical Centers

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Overview

1.1 Product Overview and Scope of Recurrent Glioblastoma Multiforme (GBM) Treatment

1.2 Classification of Recurrent Glioblastoma Multiforme (GBM) Treatment by Types

1.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Comparison by Types (2017-2023)

1.2.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Types in 2017

1.2.3 Oral Medications

1.2.4 Temozolomide

1.2.5 Radiosensitizers

1.2.6 Nitrosoureas Drugs

1.2.7 Radiation Therapy

1.2.8 Chemotherapy

1.3 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market by Application

1.3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market by Regions

1.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Recurrent Glioblastoma Multiforme (GBM) Treatment Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Recurrent Glioblastoma Multiforme (GBM) Treatment Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Recurrent Glioblastoma Multiforme (GBM) Treatment Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Recurrent Glioblastoma Multiforme (GBM) Treatment Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Recurrent Glioblastoma Multiforme (GBM) Treatment Status and Prospect (2013-2023)

1.5 Global Market Size of Recurrent Glioblastoma Multiforme (GBM) Treatment (2013-2023)

2 Manufacturers Profiles

2.1 Astrazeneca

2.1.1 Business Overview

2.1.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.2 Roche

2.2.1 Business Overview

2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.3 GlaxoSmithKline

2.3.1 Business Overview

2.3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.4 Merck

2.4.1 Business Overview

2.4.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.5 Pfizer

2.5.1 Business Overview

2.5.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.6 AngioChem

2.6.1 Business Overview

2.6.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2016-2017)

2.7 Vascular Biogeneics

2.7.1 Business Overview

2.7.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2016-2017)

3 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Competition, by Players

3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Recurrent Glioblastoma Multiforme (GBM) Treatment Players Market Share

3.2.2 Top 10 Recurrent Glioblastoma Multiforme (GBM) Treatment Players Market Share

3.3 Market Competition Trend

4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions

4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Market Share by Regions

4.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

4.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

4.5 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

5 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries

5.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries (2013-2018)

5.2 USA Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

5.3 Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

5.4 Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

6 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries

6.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries (2013-2018)

6.2 Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

6.3 UK Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

6.4 France Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

6.5 Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

6.6 Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries

7.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries (2013-2018)

7.2 China Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

7.3 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

7.4 Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

7.5 India Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

8 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries

8.1 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries (2013-2018)

8.2 Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

8.3 Argentina Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

8.4 Colombia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Recurrent Glioblastoma Multiforme (GBM) Treatment by Countries

9.1 Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Countries (2013-2018)

9.2 Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

9.3 UAE Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

9.4 Egypt Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

9.5 Nigeria Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

9.6 South Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2013-2018)

10 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Segment by Type

10.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Market Share by Type (2013-2018)

10.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Forecast by Type (2018-2023)

10.3 Oral Medications Revenue Growth Rate (2013-2023)

10.4 Temozolomide Revenue Growth Rate (2013-2023)

10.5 Radiosensitizers Revenue Growth Rate (2013-2023)

10.6 Nitrosoureas Drugs Revenue Growth Rate (2013-2023)

10.7 Radiation Therapy Revenue Growth Rate (2013-2023)

10.8 Chemotherapy Revenue Growth Rate (2013-2023)

11 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Segment by Application

11.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2013-2018)

11.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Clinics Revenue Growth (2013-2018)

11.5 Ambulatory Surgical Centers Revenue Growth (2013-2018)

12 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Forecast (2018-2023)

12.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Forecast (2018-2023)

12.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Forecast by Regions (2018-2023)

12.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Forecast (2018-2023)

12.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Forecast (2018-2023)

12.6 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Recurrent Glioblastoma Multiforme (GBM) Treatment Picture

Table Product Specifications of Recurrent Glioblastoma Multiforme (GBM) Treatment

Table Global Recurrent Gl

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery